Skip Navigation

Innovations

  • In the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI), our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through collaborations and relationships with industry.

    As a bridge between research and industry, BODFI is committed to building relationships with companies both large and small, with the investor community, and with entrepreneurs. Our goal is to create solutions.

  • At BODFI, we will:

  • Successful Developments

    James Griffin, MD, at the podium

    Backed by Dana-Farber research, FDA approves new AML drug

    Based on research from James Griffin, MD, the drug Rydapt, whose clinical testing was led by Richard Stone, MD, has become the first new treatment for newly diagnosed acute myeloid leukemia in over 25 years.
    Adam Bass, MD

    New study of esophageal cancer reveals ground-breaking results

    A comprehensive study of esophageal cancer, co-led by Adam Bass, MD, of Dana-Farber, reveals several molecular subtypes and provides new insight into an increasingly prevalent disease.
    Leukemia cells

    Public repository of cancer models aims to improve drug testing

    Dana-Farber has established an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma, titled The Public Repository of Xenografts (PRoXe). 

    Catherine Wu, MD

    Personalized tumor vaccines keep cancer in check

    Catherine Wu, MD, of Dana-Farber led development of a new personalized cancer vaccine that could trigger immune T cells to attack tumor cells.

  • Email Us

    General: innovation@dfci.harvard.edu
    Academic MTAs: mta@dfci.harvard.edu